A CSF Biomarker Panel to Identify Early ALS

Clinical Takeaway

: In a small observational study, a tri-protein cerebrospinal fluid panel shows some potential for diagnosing sporadic amyotrophic lateral sclerosis.

Context

Currently, no single test can definitively diagnose amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by progressive loss of upper- and lower-motor neurons. In this study, researchers aimed to (1) identify alterations among approximately 200 proteins implicated in pathways of ALS pathogenesis, and (2) create a biomarker panel to differentiate ALS patients from patients with chronic progressive limb or bulbar weakness from other causes. Using proximity extension, single-molecule, and ELISA assays, the investigators measured proteins in thawed cerebrospinal fluid (CSF) from 109 patients with newly diagnosed sporadic ALS seen at one hospital in China (mean age, 57 years; mean disease duration, 11 month…

Reviewing Author

Leana Doherty, MD

Disclosures

Editorial BoardsNeurohospitalist Society; InterACTN (Annals of Clinical and Translational Neurology)

Leana Doherty, MD

Disclosures

Editorial BoardsNeurohospitalist Society; InterACTN (Annals of Clinical and Translational Neurology)

A CSF Biomarker Panel to Identify Early ALS

Topics

Clinical Takeaway

Context

Reviewing Author